Licensing Strategies of the New "intellectual Property Vendors" Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

This case explores business strategy, product testing, and regulatory at Targanta Therapeutics, a biotech company. In the October of year 2007, Mark Leuchtenberger, president and CEO of Targanta - which has only held a successful IPO - considers choices for the about ten month review period after the company submits to the Food and Drug Administration.

Licensing Strategies of the New intellectual Property Vendors Case Study Solution

The case reviews Targanta's sources and "de-risking" of oritavancin, an antibiotic therapy for drug-resistant infections that was first devised at Eli Lilly and then spun out to InterMune before Targanta got it in late section of year 2005. To accentuate the consequence of regulatory policy on business strategy the instance then describes a set of options confronting the company, including staffing a promotion and sales group, carrying out additional clinical testing to expand the approved signs, applying for European market acceptance, or keeping funds in reserve in the event the FDA requests further data.

PUBLICATION DATE: January 13, 2009 PRODUCT #: 709002-HCB-ENG

This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP